Home › Spinal Cord Injuries › NCT05152290

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for SCI

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury

Who can join

All ages · All sexes

Inclusion Criteria:

* Diagnosis of Spinal Cord Injury
* Understanding and willingness to sign a written informed consent document

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant Abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
* Continued drug abuse
* Pre-menopausal women not using contraception
* Previous organ transplant
* Hypersensitivity to sulfur
* Anticoagulation medicine use

About the study

This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Spinal Cord Injury.

What is being tested

• cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells (biological)

Sponsor: The Foundation for Orthopaedics and Regenerative Medicine · Participants: 20 · Started: Jul 6, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05152290

Locations in the U.S.

Conditions

• Spinal Cord Injuries

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.